Detailed description page of THPdb

This page displays user query in tabular form.

1745 details

Primary information
ThPP ID	Th1180
Therapeutic Peptide/Protein Name	Fibrinogen Concentrate (Human)
Sequence	NA view full sequnce in fasta
Functional Classification	Ia
Molecular Weight	340000
Chemical Formula	NA
Isoelectric Point	NA
Hydrophobicity	NA
Melting Point (℃)	NA
Half Life	78.7 Â± 18.13 (55.73-117.26) hours
Description	Fibrinogen Concentrate (Human) is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma.
Indication/Disease	For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Pharmacodynamics	Administration of fibrinogen concentrate (human) for intravenous use to patients with congenital fibrinogen deficiency replaces the missing, or low coagulation factor. Normal levels are in the range of 200 to 450 mg/dL
Mechanism of Action	Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. The native molecule is a dimer and consists of three pairs of polypeptide chains (AÎ±, BÎ² and Î³). Fibrinogen is a physiological substrate of three enzymes: thrombin, factor XIIIa, and plasmin. During the coagulation process, thrombin cleaves the AÎ± and BÎ² chains releasing fibrinopeptides A and B (FPA and FPB, respectively).2 FPA is separated rapidly and the remaining molecule is a soluble fibrin monomer (fibrin I). The slower removal of FPB results in formation of fibrin II that is capable of polymerization that occurs by aggregation of fibrin monomers.2 The resulting fbrin is stabilized in the presence of calcium ions and by activated factor XIII, which acts as a transglutaminase. Factor XIIIa-induced cross-linking of fibrin polymers renders the fibrin clot more elastic and more resistant to fibrinolysis.3 Cross-linked fibrin is the end result of the coagulation cascade, and provides tensile strength to a primary hemostatic platelet plug and structure to the vessel wall.
Toxicity	NA
Metabolism	NA
Absorption	AUC for dose 70 mg/Kgis 124.3 Â± 24.16 (81.73-156.40) mg*hr/mL
Volume of Distribution	52.7 Â± 7.48 (36.22-67.67) mL/KG
Clearance	0.59 Â± 0.13 (0.45-0.86) mL/h/KG
Categories	NA
Patents Number	NA
Date of Issue	NA
Date of Expiry	NA
Drug Interaction	The risk or severity of adverse effects can be increased when Aminocaproic Acid is combined with Fibrinogen Concentrate (Human); The risk or severity of adverse effects can be increased when Menadione is combined with Fibrinogen Concentrate (Human); The risk or severity of adverse effects can be increased when Phylloquinone is combined with Fibrinogen Concentrate (Human); The risk or severity of adverse effects can be increased when Tranexamic Acid is combined with Fibrinogen Concentrate (Human).
Target	NA
Information of corresponding available drug in the market
Brand Name	Riastap
Company	Csl Behring Gmb H
Brand Discription	RiaSTAP (fibrinogen concentrate human for intravenous use) is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma.
Prescribed for	RiaSTAPâ„¢ (fibrinogen concentrate (human) for intravenous use) , Fibrinogen Concentrate (Human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Chemical Name	NA
Formulation	Each vial contains 900 to 1300 mg fibrinogen, 400 to 700 mg human albumin, 375 to 660 mg L-arginine hydrochloride, 200 to 350 mg sodium chloride and 50 to 100 mg sodium citrate. Sodium hydroxide and hydrochloric acid may have been used to adjust the pH.
Physcial Appearnce	injection, powder, lyophilized, for solution
Route of Administration	IV
Recommended Dosage	Dose should be individually calculated for each patient based on the target plasma fibrinogen level based on the type of bleeding, actual measured plasma fibrinogen level and body weight
Contraindication	RiaSTAP (fibrinogen concentrate (human) for intravenous use) is contraindicated in individuals who have manifested severe immediate hypersensitivity reactions, including anaphylaxis to RiaSTAP (fibrinogen concentrate (human) for intravenous use) or its components.
Side Effects	The most serious adverse reactions that have been reported in clinical studies or through postmarketing surveillance following RiaSTAP (fibrinogen concentrate (human) for intravenous use) treatment are allergic-anaphylactic reactions and thromboembolic episodes, including myocardial infarction, pulmonary embolism, deep vein thrombosis, and arterial thrombosis. The most common adverse reactions that have been reported in clinical studies or through postmarketing surveillance following RiaSTAP (fibrinogen concentrate (human) for intravenous use) treatment are allergic reactions and generalized reactions such as chills, fever, nausea, and vomiting.
Useful Link	http://www.rxlist.com/riastap-drug/side-effects-interactions.htm
PubMed ID	18179679
3-D Structure	N.A.